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RISK FACTORS OF HIV-1 VERTICAL TRANSMISSION (VT) AND THE INFLUENCE OF 
ANTIRETROVIRAL THERAPY (ART) IN PREGNANCY OUTCOME
Maria F.M. BARRAL, Gisele R. de OLIVEIRA, Rubens C. LOBATO, Raul A. MENDOZA-SASSI, Ana M.B. MARTÍNEZ & Carla V. GONÇALVES
SUMMARY
In the absence of intervention, the rate of vertical transmission of HIV can range from 15-45%. With the inclusion of antiretroviral 
drugs during pregnancy and the choice of delivery route this amounts to less than 2%. However ARV use during pregnancy has generated 
several questions regarding the adverse effects of the gestational and neonatal outcome. This study aims to analyze the risk factors for 
vertical transmission of HIV-1 seropositive pregnant women living in Rio Grande and the influence of the use of ARVs in pregnancy 
outcome. Among the 262 pregnant women studied the rate of vertical transmission of HIV was found to be 3.8%. Regarding the VT, 
there was a lower risk of transmission when antiretroviral drugs were used and prenatal care was conducted at the referral service. 
However, the use of ART did not influence the outcome of pregnancy. However, initiation of prenatal care after the first trimester had 
an influence on low birth weight, as well as performance of less than six visits increased the risk of prematurity. Therefore, the risk 
factors analyzed in this study appear to be related to the realization of inadequate pre-natal and maternal behavior.
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INTRODUCTION
According to UNAIDS, 34 million people are infected with HIV 
worldwide. Among them, 30 million are adults and 16.8 million women27. 
In Brazil, from 1980 to June 2011 608,230 cases of Aids were reported 
and over the past 12 years a stabilization of the incidence rates has 
been observed3. In 2010, the sex ratio was 1.7 new cases in men to one 
case in women, 71% of infected women are of reproductive age, with a 
prevalence of 0.4% of infected pregnant women2,3.
In the absence of intervention, the rates of HIV transmission during 
pregnancy, labor or breastfeeding vary from 15-45%. Related to maternal-
to-child transmission (MTCT), 35% occur during pregnancy, 65% in the 
peripartum and the risk of transmission through breastfeeding varies from 
7% to 22%. Besides obstetric and neonatal variables, maternal variables 
such as viral load, advanced disease, co-infections, delay or non-use of 
antiretroviral (ARV) at the beginning or during pregnancy influence risk 
of HIV MTCT5,18.
Vertical HIV transmission (VT) rates can be reduced to levels 
below 2% if women living with HIV have a suitable attendance during 
pregnancy with the use of ARV and reduce of the viral load (VL)6. In 
Brazil between 1980 and 2011 there were 14,127 cases of Aids in children 
under five. Over the last 12 years a 49.1% reduction in the absolute 
number of cases and 40.7% in the incidence rate3 was observed. However, 
a multicenter study conducted by the Brazilian Society of Pediatrics in 
2004 showed that the rate of HIV MTCT in Brazil was 6.8%8.
There are still several barriers to effective prevention of perinatal 
transmission of HIV both related to female behavioral characteristics, as 
well as the quality of clinical services provided to them8,10,24. Although 
the main and the most effective way to reduce to VL, use of ART during 
pregnancy has generated conflicting data about possible adverse effects to 
the neonate7, such as: preterm delivery1,17, low birth weight22, a decrease 
in neurological function28, and low Apgar scores1. However, to date, there 
is no consensus on the association between antiretroviral drugs used by 
women during pregnancy and their consequences. Until now there is 
no sufficient evidence to support that the combined use of ARV has a 
negative association with pregnancy outcome1,7,8,10,17,22,28.
The current study aimed to analyze the risk factors associated with 
vertical transmission of pregnant HIV-infected women in the city of 
Rio Grande and the influence of ART in pregnancy outcome such as 
prematurity, Apgar score and low birth weight.
MATERIAL AND METHODS
This study was conducted in Rio Grande, located in the southern 
coastal plain of Rio Grande do Sul, Brazil. The primary health care system 
is composed of 32 primary care units (PCU), and two general hospitals. 
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Health care for people living with HIV is offered by a specialized unit at 
the University Hospital Miguel Riet Correa Junior (HU-FURG). In 2003, 
a specific unit for seropositive pregnant women was created. Every patient 
has a medical record with information from ongoing prenatal, delivery 
and HIV MTCT. This cohort study included all pregnant women that 
attended the HU-FURG between July 2003 and July 2007. This endpoint 
date was chosen because until this period there were 95 women using 
Biovir® and Nelfinavir® and the same number using Biovir® and Kaletra®. 
The study was submitted and approved by the Ethical Committee of 
FURG (23116001368/2003-44 protocol). All procedures were carried 
out in accordance with the guidelines of the Helsinki Declaration.
The independent variables measured were: maternal age, years of 
schooling, number of pregnancies, parity, trimester of prenatal care 
initiation, number of prenatal visits, location of prenatal care (HU-FURG, 
other facilities, or no prenatal care), type of delivery, fasting glucose in 
the first or third trimester (≥ 86 mg/dL), CD4 + ≥ 350 count and viral 
load of the mother (≥ 1000 copies).
An aliquot of blood was collected from all pregnant women in the 
thirty fourth week of gestation for viral load quantification and CD4+T 
lymphocytes count. The use of ARV was categorized by time in two 
groups (cutoff 9/10 weeks). The type of ARV exposure was classified as: 
no use, use of Biovir® and Nelfinavir®, Kaletra® and Biovir®, other ARV. 
Outcomes studied were: birth weight ≤ 2500 g, fifth minute Apgar score 
≤ 7; delivery at less than 37 weeks of gestation and HIV VT.
Status of viral infection of the newborn and time of transmission 
was determined by the technique of Polymerase Chain Reaction (PCR) 
from pro-viral DNA extracted (commercial kit ® Illustra blood genomic 
Prep Mini Spin, GE Healthcare ®) from the first blood collection (24/48 
hours), and at 30 and 60 days after birth.
Multivariate analysis was based on an analysis model using Poisson 
regression with robust adjustment of variance. After calculating 
prevalence ratios (PR) and their respective confidence intervals of 95% 
(95% CI), variables that had a p-value ≤ 0.20 in the bivariate analysis 
were included in the model. For the birth weight ≤ 2500g outcome the 
variables included were: number of births, start of prenatal care trimester, 
and time of use of ARV. Adjusted analysis of Apgar score ≤ 7 at the fifth 
minute included: maternal age and schooling years, number of prenatal 
care visits, site of prenatal care, fasting glucose, viral load, ARV use 
and time of ART. For pre-term birth ≤ 37 weeks the following variables 
were analyzed: number of prenatal care visits, fasting glucose, and use 
of ARV. VT outcome was adjusted for: location of prenatal care, delivery 
type, CD4, viral load, time and use of ARV. The Wald test was used for 
statistical analysis and a p-value equal to or less than 0.05 of a two-tailed 
test was considered as significant.
RESULTS
The study included a total of 262 women with a mean age of 27 
years (SD ± 6.24). 68.7% had four or less years of schooling and the 
number of pregnancies was on average 2.58 (SD ± 2.21) with a parity 
of 2.09 (SD ± 1.82 ).
The location of prenatal care was HU- FURG in 83.5% of cases, 
onset of prenatal care was on average 16 weeks of pregnancy, carrying 
around five visits each. Type of delivery was cesarean section in 61.5% 
of cases. Average weight of newborns was 2894g and Apgar score at 
five minutes was 9. Delivery was on average at 40 weeks of gestation. 
Regarding to the HIV status, the mean of CD4 + T cells was 574 cel/
uL, the viral load was 10,603 copies/mL at 34 weeks of pregnancy and 
time of use of ARV was 16 weeks (SD ± 2.42).
Table 1 shows the results of the prevalence ratio (PR) and their 
Confidence Interval (95%CI). None of the studied factors showed 
significant association with the outcomes low birth weight and preterm 
birth. For the outcome fifth minute Apgar ≤ 7, women who had less than 
five visits had a PR 2.18 (1.08 to 4.40) and those with fasting glucose ≥ 
86 mg/dL had PR of 2.42 (1.26 to 4.63). On the other hand, a lower risk 
of low Apgar score was observed (PR 0.47; CI: 0.26-1.66) in infants born 
from pregnant women with longer use of ARV (≥ 10 weeks).
From the 262 pregnant women, 10 (3.8%) transmitted HIV to the 
newborns. In the bivariate analysis those with three or more pregnancies 
had an increased risk of virus transmission (p = 0.05). The prenatal 
location also showed a significant association with the risk of MTCT, 
when held in a location other than the University Hospital (PR 9.37; 
95% CI: 2.51 to 34.9) and in case of lack of prenatal (PR 2.90; CI: 0.59-
14.24). Furthermore, maternal viral load ≥ 1000 was associated with a 
higher prevalence ratio (PR: 4.98; CI: 1.32-18.7) of HIV transmission to 
the newborn. The non-use of ARV was also related to increased risk of 
transmission (RP 12.9 p = 0.003), the use of Biovir ® and Nelfinavir® had 
a prevalence rate increased by three times (PR 3.0 p = 0.003) compared 
to the use of Biovir ® and Kaletra ®.
In the multivariate analysis (Table 2), after adjustment for selected 
variables from the bivariate analysis, it was observed that low birth weight 
(≤ 2500 g) had a higher probability of occurring when the start of prenatal 
care occurred in the 3rd trimester (PR 1.07; CI: 1.01-1.14). Regarding the 
pre-term birth (≤ 37 weeks), five or less visits had a higher probability of 
outcome (PR1.08; CI: 1.02-1.15). Finally, association of HIV VT with 
the use of ARV remained significant, with use of Biovir® and Kaletra® 
featuring a lower likelihood of outcome (PR 0.09; CI: 0.01-0.73), and 
prenatal location losing statistical significance.
DISCUSSION
The present study showed that undesirable pregnancy outcomes in 
women with HIV was associated to variables related to prenatal care and 
that VT was lower with use of Biovir® and Kaletra® and when prenatal 
care was taken under a specialized center. Among possible limitations is 
the fact that although HU-FURG is the only referral center for pregnant 
HIV-infected women of Rio Grande, some cases of prenatal care and 
delivery might have happened outside this service. Thus, pregnant 
women who had labor outside HU-FURG were lost in this study. Data 
from women who had their pregnancy monitoring outside HU-FURG, 
but delivery performed in this hospital, were registered in our system 
retroactively to childbirth.
Currently, Aids is a major public health problem worldwide. 
Clinical status of pregnant HIV-infected women has improved 
considerably with the introduction of ART. This resulted in decreased 
rates of HIV MTCT6,10,23,25. Nonetheless, studies have reported that 
despite the benefits of ART during pregnancy, some women exposed 
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Table 1
Adverse pregnancy outcome factors associated with HIV-infected women
Variable
Weight ≤ 2500g Apgar ≤ 7 Delivery before ≤ 37 weeks HIV vertical transmission
N (%) PR (95%CI) N (%) PR (95%CI) N (%) PR (95%CI) N (%) PR (95%CI)
Age (years)
   30 or more
   20 to 29
   19 or less
Schooling (years)
   5 years or more
   4 years or less
Pregnancies
   One
   Two
   3 or more
Parity
   Pimiparous
   Multiparous
Start of prenatal care
   1° trimester
   2° trimester
   3° trimester 
Number of visits
   ≥  6 visits
   ≤ 5 visits
Prenatal care location
   University Hospital
   Other facilities
   No prenatal care
Type of delivery
   Cesarean section 
   Vaginal
Fasting glucose 
   ≤ 85 mg/dL
   ≥ 86 mg/dL
CD4
   ≥ 350
   ≤ 349
Viral load
   ≤ 999
   ≥ 1000
Antirretroviral
   No  ARV
   Biovir e Nelfinavir 
   Biovir e Kaletra
   Other ARV
Time of use of ARV
   ≤ 9 weeks
   ≥ 10 weeks
15 (19.5)
26 (19.1)
2 (7.1)
17 (13.9)
8 (14.0)
6 (12.5)
10 (18.5)
17 (19.5)
8 (11.9)
24 (20.2)
17 (19.5)
18 (22.0)
2 (5.3)
16(15.0)
22 (20.8)
35 (17.4)
3 (30.0)
4 (16.0)
26 (17.4)
17 (18.3)
31 (18.9)
6 (14.3)
30 (17.8)
10 (18.2)
24 (15.9)
16 (22.5)
7 (16.7)
12 (12.8)
20 (23.8)
3 (18.8)
8 (12.3)
29 (19.9)
p = 0.29
1.0
0.37 (0.09-1.50)
0.98 (0.55-1.74)
p = 0.98
1.0
0.99 (0.46-2.16)
p = 0.57
1.0
1.48 (0.58-3.77)
1.56 (0.66-3.70)
p = 0.15
1.0
1.69 (0.00-3.55)
p = 0.07
1.0
1.12 (0.62-2.03)
0.27 (0.07-1.11)
p = 0.26
1.0
0.99 (0.46-2.16)
p = 0.98
1.0
1.72 (0.64-4.65)
0.92 (0.36-2.37)
p = 0.87
1.0
1.05 (0.60-1.82)
p = 0.48
1.0
0.76 (0.34-1.65)
p = 0.98
1.0
1.02 (0.54-1.96)
p = 0.23
1.0
1.42 (0.00-2.50)
p = 0.29
1.0
0.77 (0.32-1.81)
1.43 (0.60-3.11)
1.13 (0.33-3.83)
p = 0.18
1.0
1.61 (0.78-3.34)
16 (24.6)
16 (13.9)
6 (25.0)
4 (8.2)
18 (18.4)
6 (13.3)
8 (18.2)
11 (15.9)
10 (18.2)
16 (15.8)
11 (13.8)
12 (16.4)
6 (20.0)
10 (10.3)
20 (22.5)
31 (17.0)
0 (0.0)
8 (47.1)
22 (16.7)
17 (23.6)
20 (13.8)
10 (27.8)
25 (16.9)
8 (18.6)
19 (14.4)
13 (22.4)
10 (32.3)
9 (12.2)
18 (22.0)
2 (12.3)
16 (22.5)
19 (15.9)
p = 0.14
1.0
0.57 (0.30-1.05)
1.02 (0.45-2.29)
p = 0.10
1.0
2.25 (0.81-6.29)
p = 0.82
1.0
1.36 (0.52-3.61)
1.20 (0.48-3.00)
p = 0.70
1.0
0.87 (0.42-1.79)
p = 0.71
1.0
1.20 (0.56-2.54)
1.45 (0.59-3.58)
p = 0.02
1.0
2.18 (1.08-4.40)
p = 0.07
1.0
---
2.76 (1.52-5.02)
p = 0.22
1.0
1.42 (0.81-2.49)
p = 0.04
1.0
2.42 (1.26-4.63)
p = 0.79
1.0
1.10 (0.54-2.26)
p = 0.17
1.0
1.56 (0.83-2.94)
p = 0.09
1.0
0.38 (0.17-0.84)
0.68 (0.35-1.31)
0.41 (0.10-1.66)
p = 0.01
1.0
0.47 (0.26-1.66)
19 (24.7)
26 (19.3)
6 (21.4)
11 (19.3)
21 (17.4)
10 (20.8)
10 (18.5)
17 (19.8)
11 (16.4)
27 (22.9)
17 (19.5)
21 (25.6)
6 (15.8)
15 (14.0)
29 (27.4)
43 (21.4)
1 (10.0)
6 (25.0)
34 (22.8)
17 (18.5)
32 (19.5)
13 (31.0)
36 (21.4)
9 (16.4)
33 (16.9)
12 (21.9)
10 (24.4)
13 (13.8)
22 (26.2)
5 (31.3)
14 (21.9)
32 (21.9)
p = 0.65
1.0
0.78 (0.46-1.31)
0.07  (0.39-1.95)
p = 0.75
1.0
0.90 (0.47-1.74)
p = 0.95
1.0
0.89  (0.41-1.95)
0.95 (0.47-1.90)
p = 0.29
1.0
1.39 (0.74-2.63)
p = 0.41
1.0
1.31 (0.75-2.30)
0.81 (0.35-1.89)
p = 0.16
1.0
1.95 (1.11-3.43)
p = 0.61
1.0
0.47 (0.07-3.06)
1.17 (0.56-2.45)
p = 0.42
1.0
0.81 (0.48-1.36)
p = 0.10
1.0
1.59 (0.92-2.74)
p = 0.41
1.0
1.10 (0.54-2.26)
p = 0.39
1.0
0.77 (0.43-1.41)
p = 0.13
1.0
0.57 (0.27-1.19)
1.07 (0.56-2.05)
1.28 (0.52-3.17)
p = 0.99
1.0
1.0 (0.58-1.75)
4 (4.9)
4 (2.8)
2 (6.5)
7 (5.5)
3 (5.0)
0 (0.0)
 2 (3.6)
8 (8.9)
3 (4.1)
7 (5.7)
4 (4.3)
3 (3.3)
3 (7.7)
4 (3.6)
6 (5.2)
5 (2.5)
3 (23.1)
2 (7.1)
4 (2.7)
6 (6.3)
7 (4.0)
3 (6.7)
7 (3.9)
3 (5.2)
3 (1.9)
7 (9.3)
6 (13.6)
3 (3.2)
1 (1.1)
0 (0.0)
10 (15.2)
0 (0.0)
p = 0.52
1.0
0.56 (0.14-2.17)
1.31 (0.25-6.78)
p = 0.88
1.0
1.10 (0.30-4.12)
p = 0.05
1.0
----
-----
p = 0.60
1.0
1.42 (0.38-5.31)
p = 0.54
1.0
0.77 (0.18-3.37)
1.79 (0.42-7.62)
p = 0.54
1.0
1.46 (0.42-5.04)
p = 0.001
1.0
9.37 (2.51-34.9)
2.90(0.59-14.24)
p = 0.16
1.0
1.32 (0.69-8.17)
p = 0.43
1.0
1.68 (0.45-6.23)
p = 0.16
1.0
1.32 (0.35-4.95)
p = 0.008
1.0
4.98 (1.32-18.7)
p = 0.003
12.9 (1.61-104.3)
3.00 (0.32-28.3)
1.0
----
p = 0.001
1.0
----
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to ARV showed anemia, nausea, vomiting, hyperglycemia and elevated 
aminotransferase1,18. 
Most studies showed that the use of Biovir ®during pregnancy has 
not been associated with an increased risk of teratogenicity4,26, low birth 
weight, smaller head circumference, cognitive dysfunction and preterm 
delivery1,4,17,22,28. However, research shows that the use of protease 
inhibitors (Nelfinavir® and Kaletra®) could be associated to an increased 
risk of preterm birth11,19, although no association with low birth weight 
and lower Apgar score was found18,26,27,28 ,29.
In the bivariate analysis no significance was found between low 
birth weight and preterm birth and the other variables. After multivariate 
analysis, women who started prenatal care in the third trimester had 
a 7% higher risk of having infants with low birth weight. Likewise, 
pregnant women who had five or less visits had an increased risk of 
8% for delivering before 37 weeks of gestation. In accordance to other 
published studies6,1,12,18,23 this research found no negative association of 
ART and low birth weight or prematurity. 
Highest prevalence of preterm delivery and low birth weight has 
been associated with elective cesarean section9,12,13,20. Studies show that 
the current indication for elective cesarean, although decreasing the risk 
of transmission, may increase the prevalence of preterm births when 
performed before 38 weeks11,13,14,22. In our study the prevalence of delivery 
with less than 37 weeks was 22.8% among women undergoing cesarean 
section and 18.5% among women who gave birth vaginally. The high 
prevalence of caesarean section in this study is related to maternal viral 
load greater than or equal to 1000 copies/mL (32.1%) or your ignorance 
after the 34th week (11.1%). We emphasize the importance of accurate 
assessment of gestational age (GA) with a first trimester ultrasound and 
date of last menstrual period compatible (LMP), when it is necessary to 
indicate elective cesarean section in this group. 
In this study, the use of ART showed no association with a low score 
in the 5th minute Apgar. YOSHIMOTO et al. (2005)29, investigating the 
clinical and laboratory evolution of neonates from HIV-infected mothers, 
reported no relation between Apgar score and presence of HIV. Other 
studies in Brazil showed that the Apgar score in newborns of mothers 
with HIV was higher than seven in the first and fifth minute, not being 
related with the HIV infection. Values less than seven are associated 
with unfavorable outcomes during childbirth, especially neonatal 
asphyxia16,24,30.
HIV MTCT rate in this study was 3.8%. Among the factors that 
influenced HIV transmission are prenatal care outside the HIV service 
and non-use of combined ARV. After multivariate analysis, a 7-fold 
risk of transmitting HIV to the newborns was observed when women 
received prenatal care outside the reference service (HU-FURG). 
Probably the women who received prenatal care outside the reference 
service (HU-FURG) did not use or started using ARVs late. A fact 
that may have influenced a higher viral load in these women at greater 
risk and consequent VT. The Brazilian government has guidelines for 
the management of pregnant women with HIV, which emphasize the 
importance of early referral of pregnant women to a reference service2. 
Another factor that influenced MTCT was the ART, women who used 
Biovir® and Kaletra® during pregnancy had 91% less risk of transmitting 
HIV to the neonates when compared with women who did not use ARV. 
Already using Biovir® and Nelfinavir® reduced the risk of MTCT by 
88% compared to not using ARVs. TORNATORE et al. (2010)23 in the 
same city demonstrated that the use of ARV during pregnancy lowers 
the risk of VT by 68%.
The association between quality of prenatal care and pregnancy 
outcome is well established21. This study demonstrated that pregnant 
women with HIV, having adequate care, are susceptible to the very same 
factors that affect pregnancy outcomes in non-HIV women. Therefore, a 
Table 2
Adjusted analysis for unfavorable pregnancy outcome factors associated with HIV-infected women
Outcome Variable Prevalence Ratio (95%CI) p -value
Low birth weight ( ≤ 2500g)
Delivery ≤ 37 weeks
HIV Vertical Transmission
Start of prenatal care
1st trimester
2nd trimester
3rd trimester 
Number of visits
≥  6 visits
≤ 5 visits
Prenatal care location
University Hospital
Other facilities
No prenatal care 
Antirretroviral
No ARV
Biovir and Nelfinavir
Biovir and Kaletra
Other ARV
1.0
0.98 (0.92-1.05)
1.07 (1.01-1.14)
1.0
1.08 (1.02 - 1.15)
1.0
7.61 (1.04 - 55.57)
2.31 (0.21 - 24.75)
1.0
0.21 (0.05 - 1.00)
0.09 (0.01 - 0.73)
0.005
0.013
0.06
0.041
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proper prenatal care and initiation in the first trimester of pregnancy are 
crucial for avoiding risk associated with an unfavorable outcome. The 
rate of mother to child transmission of HIV becomes almost zero when 
these appropriate measures are taken. Despite the possible risks of using 
ARV by the mother during pregnancy, the benefits to the newborn are 
compensatory and its use did not influence the outcome of pregnancy. 
Undesirable outcomes (birth weight ≤ 2500g, Apgar score ≤ 7 in the 
fifth minute, delivery ≤ 37 weeks and HIV MTCT) seem to be related to 
the realization of inadequate prenatal care and maternal behavior. More 
research on the subject is essential, including studies analyzing long 
term effects in children who were exposed to ARV during pregnancy.
RESUMO
Fatores de risco para a transmissão vertical do HIV-1 e a 
influência da terapia antirretroviral (ARV) no desfecho 
gestacional
Na ausência de intervenção, as taxas de transmissão vertical do HIV 
podem variar de 15-45%. Com a inserção dos antirretrovirais durante a 
gestação e a escolha da via de parto estas taxas chegam a menos de 2%. 
No entanto o uso de ARV na gestação tem gerado várias duvidas quanto 
aos efeitos adversos causados ao desfecho gestacional e ao neonato. 
Este estudo objetiva analisar os fatores de risco da transmissão vertical 
do HIV-1 em gestantes soropositivas atendidas na cidade do Rio Grande 
e a influência do uso do ARV no desfecho gestacional. Entre as 262 
gestantes estudadas a taxa de transmissão vertical do HIV encontrada 
foi de 3,8%. Em relação à TV, foi observado menor risco de transmissão 
quando esta havia feito uso de antirretrovirais e o pré-natal era realizado 
no serviço de referência. Entretanto, o uso de ARV não influenciou 
negativamente o desfecho gestacional. No entanto, o inicio do pré-natal 
após o primeiro trimestre teve influencia sobre o baixo peso ao nascer, 
assim como a realização de menos de seis consultas aumentou o risco 
de prematuridade. Portanto, os fatores de risco analisados neste estudo 
parecem estar relacionados à realização não adequada do pré-natal e ao 
comportamento materno. 
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